Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion was ordered in a first-instance ruling to pay approx. KRW 12.71B in a lawsuit filed by Humasis regarding COVID-19 diagnostic kit supply contracts, and plans to file an appeal.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decisions or Rulings on Lawsuits (Claims Exceeding Specific Amount)
- Case Name & Case Number: Payment for Goods / 2023Gahap100211
- Plaintiff: Humasis Co., Ltd.
- Defendant: Celltrion, Inc.
- Jurisdiction: Suwon District Court (Anyang Branch)
- Awarded Amount: KRW 12,710,724,105 (approx. KRW 12.71B / USD 2,094,300 + KRW 9,863,732,685, applied exchange rate: USD/KRW 1,359.40)
- Ratio to Equity: 0.07% (Based on total equity of KRW 17,580,062,368,691)
- Court Order Summary:
- Defendant (Celltrion) shall pay Plaintiff (Humasis) USD 2,094,300 and KRW 9,863,732,685 plus late payment interest
- Plaintiff’s remaining claims dismissed
- 90% of litigation costs to be borne by Plaintiff, 10% by Defendant
- Provisional execution permitted
- Background: Claims for unpaid supply contract balances and damages related to joint COVID-19 diagnostic kit business
- Future Plan: Celltrion plans to file an appeal and actively respond through legal proceedings
- Date of Ruling & Confirmation Date: July 3, 2025
- Notes: As the official court order was not yet received at the time of filing, a corrected disclosure will be filed upon receipt.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Court Judgment Receipt, Corrected Filing, and Appeal Submission
This disclosure details the 1st instance court decision requiring Celltrion to pay approx. KRW 12.71B to Humasis, making it important to monitor the filing of a corrected disclosure upon receiving the formal judgment and the submission of the appeal. Tracking the appellate process ensures verification of final legal liability status. Post-receipt updates and appellate proceedings can be verified through upcoming corrected disclosures or periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
